Benefit-And-Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease

September 1981

NTIS order #PB82-118910



CASE STUDY #11

THE IMPLICATIONS OF COST-EFFECTIVENESS ANALYSIS OF MEDICAL TECHNOLOGY

SEPTEMBER 1981

BACKGROUND PAPER #2: CASE STUDIES OF MEDICAL TECHNOLOGIES

CASE STUDY #n: BENEFIT-AND-COST ANALYSIS OF MEDICAL INTERVENTIONS: THE CASE OF CIMETIDINE AND PEPTIC ULCER DISEASE

Harvey V. Fineberg, M. D., Ph. D.
Associate Professor

and

Laurie A. Pearlman, A. B.
Research Analyst

Harvard School of Public Health, Boston, Mass.

OTA Background Papers are documents that contain information believed to be useful to various parties. The information under-girds formal OTA assessments or is an outcome of internal exploratory planning and evaluation. The material is usually not of immediate policy interest such as is contained in an OTA Report or Technical Memorandum, nor does it present options for Congress to consider.

CONGRESS OF THE UNITED STATES
Office of Technology Assessment
Washington D C 20510

Library of Congress Catalog Card Number 80-600161

For sale by the Superintendent of Documents,
U.S. Government Printing Office, Washington, D.C. 20402

Foreword

This case study is one of 17 studies comprising Background Paper #2 for OTA's assessment, *The implications of* Cost-Effectiveness *A Analysis* of *Medical* Technology. That assessment analyzes the feasibility, implications, and value of using cost-effectiveness and cost-benefit analysis (CEA/CBA) in health care decisionmaking. The major, policy-oriented report of the assessment was published in August 1980. In addition to Background Paper #2, there are four other background papers being published in conjunction with the assessment: 1) a document which addresses methodological issues and reviews the CEA/CBA literature, published in September 1980; 2) a case study of the efficacy and cost-effectiveness of psychotherapy, published in October 1980; 3) a case study of four-common diagnostic X-ray procedures, to be published in summer 198 1; and 4) a review of international experience in managing medical technology, published in October 1980. Another related report was published in September of 1979: A Review of *Selected Federal Vaccine and Immunization Policies.*

The case studies in *Background Paper* #2: Case Studies of Medical *Technologies* a r-e being published individually. They were commissioned by OTA both to provide information on the specific technologies and to gain lessons that could be applied to the broader policy aspects of the use of CEA/CBA. Several of the studies were specifically requested by the Senate Committee on Finance.

Drafts of each case study were reviewed by OTA staff; by members of the advisory panel to the overall assessment, chaired by Dr. John Hogness; by members of the Health Program Advisory Committee, chaired by Dr. Frederick Robbins; and by numerous other experts i n clinical medicine, health policy, Government, and economics. We are grateful for their assistance. However, responsibility for the case studies remains with the authors.



JOHN H. GIBBONS
Director

Advisory Panel on The Implications of Cost-Effectiveness Analysis of Medical Technology

John R. Hogness, Panel *Chairman*
President, Association of *Academic Health Centers*

Stuart H. Altman
Dean
Florence Heller School
Brandeis University

James L. Bennington
Chairman
Department of Anatomic Pathology and Clinical Laboratories
Children's Hospital of San Francisco

John D. Chase
Associate Dean for Clinical Affairs
University of Washington School of Medicine

Joseph Fletcher
Visiting Scholar
Medical Ethics
School of Medicine
University of Virginia

Clark C. Havighurst
Professor of Law
School of Law
Duke University

Sheldon Leonard
Manager
Regulatory Affairs
General Electric Co.

Barbara J. McNeil
Department of Radiology
Peter Bent Brigham Hospital

Robert H. Moser
Executive Vice President
American College of Physicians

Frederick Mosteller
Chairman
Department of Biostatistics
Harvard University

Robert M. Sigmond
Advisor on Hospital Affairs
Blue Cross and Blue Shield Associations

Jane Sisk Willems
VA Scholar
Veterans Administration

OTA Staff for Background Paper #2

Joyce C. Lashof, *Assistant Director, OTA*
Health and Life Sciences Division

H. David Banta, *Health Program Manager*

Clyde J. Behney, *Project Director*

Kerry Britten Kemp, * *Editor*
Virginia Cwalina, *Research Assistant*
Shirley Ann Gayheart, *Secretary*
Nancy L. Kenney, *Secretary*
Martha Finney, * *Assistant Editor*

Other Contributing Staff

Bryan R. Luce Lawrence Miike Michael A. Riddiough
Leonard Saxe Chester Strobe]*

OTA Publishing Staff

John C. Holmes, *Publishing* Officer

John Bergling Kathie S. Boss Debra M. Datcher Joe Henson

● OTA contract personnel.

Preface

This case study is one of 17 that comprise Background Paper #2 to the OTA project on the *lmplications of Cost-Effectiveness Analysis of Medical Technology*.* The overall project was requested by the Senate Committee on Labor and Human Resources. In all, 19 case studies of technological applications were commissioned as part of that project. Three of the 19 were specifically requested by the Senate Committee on Finance: psychotherapy, which was issued separately as Background Paper #3; diagnostic X-ray, which will be issued as Background Paper #.5; and respiratory therapies, which will be included as part of this series. The other 16 case studies were selected by OTA staff.

In order to select those 16 case studies, OTA, in consultation with the advisory panel to the overall project, developed a set of selection criteria. Those criteria were designed to ensure that as a group the case studies would provide:

- examples of types of technologies by function (preventive, diagnostic, therapeutic, and rehabilitative);
- examples of types of technologies by physical nature (drugs, devices, and procedures);
- examples of technologies in different stages of development and diffusion (new, emerging, and established);
- examples from different areas of medicine (such as general medical practice, pediatrics, radiology, and surgery);
- examples addressing medical problems that are important because of their high frequency or significant impacts (such as Cost);
- examples of technologies with associated high costs either because of high volume (for low-cost technologies) or high individual costs;
- examples that could provide informative material relating to the broader policy and methodological issues of cost-effectiveness or cost-benefit analysis (CEA/CBA); and
- examples with sufficient evaluable literature.

On the basis of these criteria and recommendations by panel members and other experts, OTA staff selected the other case studies. These 16 plus the respiratory therapy case study requested by the Finance Committee make up the 17 studies in this background paper.

All case studies were commissioned by OTA and performed under contract by experts in academia. They are authored studies. OTA subjected each case study to an extensive review process. Initial drafts of cases were reviewed by OTA staff and by members of the advisory panel to the project. Comments were provided to authors, along with OTA's suggestions for revisions. Subsequent drafts were sent by OTA to numerous experts for review and comment. Each case was seen by at least 20, and some by 40 or more, outside reviewers. These reviewers were from relevant Government agencies, professional societies, consumer and public interest groups, medical practice, and academic medicine. Academicians such as economists and decision analysts also reviewed the cases. In all, over 400 separate individuals or organizations reviewed one or more case studies. Although all these reviewers cannot be acknowledged individually, OTA is very grateful for their comments and advice. In addition, the authors of the case studies themselves often sent drafts to reviewers and incorporated their comments.



*Office of Technology Assessment, U.S. Congress, *The Implications of Cost-Effectiveness Analysis of Medical Technology*, GPO stock No. 052-003-00765-7 (Washington, D.C.: U.S. Government Printing Office, August 1980).



The case studies were selected and designed to fulfill two functions. The first, and primary, purpose was to provide OTA with specific information that could be used in formulating general conclusions regarding the feasibility and implications of applying CEA/CBA in health care. By examining the 19 cases as a group and looking for common problems or strengths in the techniques of CEA/CBA, OTA was able to better analyze the potential contribution that these techniques might make to the management of medical technologies and health care costs and quality. The second function of the cases was to provide useful information on the specific technologies covered. However, this was not the major intent of the cases, and



Some of the case studies are formal CEAS or CBAs; most are not. Some are primarily concerned with analysis of costs; others are more concerned with analysis of efficacy or effectiveness. Some, such as the study on end-stage renal disease, examine the role that formal analysis of costs and benefits can play in policy formulation. Others, such as the one on breast cancer surgery, illustrate how influences other than costs can determine the patterns of use of a technology. In other words, each looks at evaluation of the costs and the benefits of medical technologies from a slightly different perspective. The reader is encouraged to read this study in the context of the overall assessment's objectives in order to gain a feeling for the potential role that CEA/CBA can or cannot play in health care and to better understand the difficulties and complexities involved in applying CEA/CBA to specific medical technologies.

The 17 case studies comprising *Background Paper #2* (short titles) and their authors are:

Artificial Heart: Deborah P. Lubeck and John P. Bunker
Automated Multichannel Chemistry Analyzers: Milton C. Weinstein and Laurie A. Pearlman
Bone Marrow Transplants: Stuart O. Schweitzer and C. C. Scalzi
Breast Cancer Surgery: Karen Schachter and Duncan Neuhauser
Cardiac Radionuclide Imaging: William B. Stason and Eric Fortess
Cervical Cancer Screening: Bryan R. Luce

Colon Cancer Screening: David M. Eddy"'
CT Scanning: Judith L. Wagner
Elective Hysterectomy: Carol Korenbrot, Ann B. Flood, Michael Higgins," Noralou ROOS, and John P. Bunker
End-Stage Renal Disease: Richard A. Rettig
Gastrointestinal Endoscopy: Jonathan A. Showstack and Steven A. Schroeder
Neonatal Intensive Care: Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen
Nurse Practitioners: Lauren LeRoy and Sharon Solkowitz
Orthopedic Joint Prosthetic Implants: Judith D. Bentkover and Philip G. Drew
Periodontal Disease Interventions: Richard M. Scheffler and Sheldon Rovin
Selected Respiratory Therapies: Richard M. Scheffler and Morgan Delaney

These studies will be available for sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. Call OTA's Publishing Office (224-8996) for availability and ordering information.

Case Study #11

Benefit-and-Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease

Harvey V. Fineberg, M. D., Ph.D.
Associate Professor

and

Laurie A. Pearlman, A.B.
Research Analyst

Harvard School of Public Health
Boston, Mass.

AUTHORS' ACKNOWLEDGMENTS

A number of people aided us at various stages in the preparation of this report. For their valuable advice, we would like to thank Dr. Morton I, Grossman, Center for Ulcer Research and Education, Veterans Administration Center, Los Angeles; Dr. Thomas P. Al my, Dartmouth Medical School; Dr. Marvin H. Sleisenger, VA Hospital Medical Service, San Francisco; Dr. Benjamin A. Barnes, Center for the Analysis of Health Practices, Harvard School of Public Health; Dr. Janet Elashoff, Center for Ulcer Research and Education, VA Center, Los Angeles; Dr. Morton Paterson, Smith-Kline Corp.; Dr. Morris Olitsky, Robinson Associates, Inc.; Dr. George von Haunalter, Dr. Virginia Chandler, Stanford Research Institute; Dr. Richard Monson, Harvard School of Public Health; and Dr. Murray C. Wylie, University of Michigan School of Public Health. Dr. Grossman also kindly shared with us a manuscript in press. Several researchers described to us their work in progress. We are especially grateful to Dr. Wylie and to Dr.]ohn F. Geweke of the University of Wisconsin Department of Economics. We thank Dr. Leighton Read of the Center for the Analysis of Health Practices for introducing us to useful literature on ulcer disease.

We also appreciate the cooperation of Mr. Charles Dennison, Mr. Donald Greenberg, and Ms. Ethel Black of the National Center for Health Statistics, who promptly responded to our numerous requests for information. Dr. Joan Standard of the Food and Drug Administration was also very helpful.

By naming people who have advised and assisted us, we do not mean to shift responsibility for any errors or misinterpretations that may appear in this case study.